<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415606</url>
  </required_header>
  <id_info>
    <org_study_id>ZM-QCC-01</org_study_id>
    <nct_id>NCT04415606</nct_id>
  </id_info>
  <brief_title>QuikClot Control+ Hemostatic Dressing Use in Mild to Moderate Bleeding</brief_title>
  <official_title>A Pre-Market, Prospective, Controlled, Multicenter, Single Blinded, Pivotal Clinical Investigation of QuikClot Control+ for Use in Mild to Moderate Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Z-Medica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Z-Medica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      QuikClot Control+ Hemostatic Dressing (QuikClot+) is indicated for temporary control of
      internal organ space bleeding for patients displaying Class III or Class IV Bleeding. It may
      also be used for control of severely bleeding wounds such as surgical wounds and traumatic
      injuries. QuikClot Control+ is also indicated for temporary control of mild to moderate
      bleeding in cardiac surgical procedures. QuikClot Control+ is also indicated for use to
      control bleeding from bone surface following sternotomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subject will not know which arm they were randomized to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of hemostasis</measure>
    <time_frame>Up to 10 minutes</time_frame>
    <description>The primary effectiveness endpoint is the rate at which subjects achieve hemostasis (grade 0 bleed) through up to 10 minutes of application and compression of the bleeding site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of hemostasis</measure>
    <time_frame>Up to 5 minutes</time_frame>
    <description>Proportion of subjects achieving hemostasis (grade 0 bleed) measured at 5 minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>QuikClot Control+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QuikClot Control+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard gauze</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard gauze per standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QuikClot Control+</intervention_name>
    <description>Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.</description>
    <arm_group_label>QuikClot Control+</arm_group_label>
    <arm_group_label>Standard gauze</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range greater than or equal to 18 years old

          -  Willing and able to give prior written informed consent

          -  Requiring cardiac surgery

        Exclusion Criteria:

          -  Subject undergoing emergency surgery for any reason

          -  Subject has active or potential infection at the surgical site or endocarditis

          -  eGFR less that lo mL per minute

          -  Subject who is currently participating in an investigational drug or another device
             trial (excluding registries)

          -  Leucopenia (WBC &lt; 3.5x 103/µL), or acute anemia (Hgb &lt; 10.0 mg/dL or 6 mmol/L), or
             thrombocytopenia (platelet count &lt; 50x 103/µL), or history of bleeding diathesis or
             coagulopathy, or HIT positive

          -  Other medical, social, or psychological conditions that, in the opinion of the
             Investigator, precludes the subject from appropriate consent or adherence to the
             protocol required follow-up exams

          -  Active illicit drug use, verbally confirmed with the patient

          -  Severe Liver dysfunction confirmed via Child-Pugh of B-C or MELD &gt; 10

          -  Female who is pregnant at screening. Confirmation by urine or serum pregnancy test

          -  Incarcerated or unable to give voluntary informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mumashir Mumtaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Pinnacle</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajesh Raju</last_name>
    <phone>475-434-0900</phone>
    <email>araju@z-medica.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nyph/Cumc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Argenziano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Argenziano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Pinncacle</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mubashir Mumtaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mubashir Mumtaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

